NCT01351584

Brief Summary

The registry aims to collect and analyse information on the antineoplastic treatment of breast cancer in daily routine practice of office-based and clinic-based medical oncologists in Germany.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4,500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2007

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2007

Completed
4.3 years until next milestone

First Submitted

Initial submission to the registry

May 9, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 11, 2011

Completed
10.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2021

Completed
Last Updated

August 28, 2025

Status Verified

August 1, 2025

Enrollment Period

14.8 years

First QC Date

May 9, 2011

Last Update Submit

August 26, 2025

Conditions

Breast Cancer

Keywords

Breast CancerAdvanced Breast CancerEpidemiologyRegistryHealth Services ResearchGermanyPalliative TreatmentAdjuvant Drug TherapyNutrition AssessmentPhysical Activity

Outcome Measures

Primary Outcomes (1)

  • Course of Antineoplastic Treatment

    5 years

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Breast cancer patients undergoing antineoplastic or antihormonal therapy.

You may qualify if:

  • Breast cancer
  • years and older
  • Antineoplastic or antihormonal treatment

You may not qualify if:

  • No breast cancer
  • Below 18 years
  • No antineoplastic or antihormonal treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (6)

  • Fietz T, Tesch H, Rauh J, Boller E, Kruggel L, Janicke M, Marschner N; TMK-Group (Tumour Registry Breast Cancer). Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer - Results from the prospective German TMK cohort study. Breast. 2017 Aug;34:122-130. doi: 10.1016/j.breast.2017.05.014. Epub 2017 Jun 3.

    PMID: 28586735BACKGROUND

  • Schroder J, Fietz T, Kohler A, Petersen V, Tesch H, Spring L, Fleitz A, Janicke M, Marschner N; TMK-Group (Tumour Registry Breast Cancer). Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer - Results from the prospective German Tumour Registry Breast Cancer cohort study. Eur J Cancer. 2017 Jul;79:139-148. doi: 10.1016/j.ejca.2017.03.031. Epub 2017 May 8.

    PMID: 28494404BACKGROUND

  • Hurtz HJ, Tesch H, Gohler T, Hutzschenreuter U, Harde J, Kruggel L, Janicke M, Marschner N; TMK-Group (Tumour Registry Breast Cancer). Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer: results from the MaTox project. Breast Cancer Res Treat. 2017 Oct;165(3):721-731. doi: 10.1007/s10549-017-4365-7. Epub 2017 Jul 5.

    PMID: 28677012BACKGROUND

  • Fietz T, Zahn MO, Kohler A, Engel E, Frank M, Kruggel L, Janicke M, Marschner N; TMK-Group (Tumour Registry Breast Cancer). Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study. Breast Cancer Res Treat. 2018 Jan;167(2):567-578. doi: 10.1007/s10549-017-4534-8. Epub 2017 Oct 13.

    PMID: 29030786BACKGROUND

  • Dorfel S, Steffens CC, Meyer D, Tesch H, Kruggel L, Frank M, Janicke M, Marschner N; TMK-Group (Tumour Registry Breast Cancer). Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study. Breast Cancer. 2018 May;25(3):275-283. doi: 10.1007/s12282-017-0823-7. Epub 2017 Dec 4.

    PMID: 29204847BACKGROUND

  • Marschner N, Trarbach T, Rauh J, Meyer D, Muller-Hagen S, Harde J, Dille S, Kruggel L, Janicke M; TMK-Group (Tumour Registry Breast Cancer). Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project. Breast Cancer Res Treat. 2019 Jun;175(3):701-712. doi: 10.1007/s10549-019-05197-w. Epub 2019 Mar 13.

    PMID: 30868393BACKGROUND

MeSH Terms

Conditions

Breast NeoplasmsMotor Activity

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesBehavior

Study Officials

  • Hans Tesch, MD

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 9, 2011

First Posted

May 11, 2011

Study Start

February 1, 2007

Primary Completion

December 1, 2021

Study Completion

December 1, 2021

Last Updated

August 28, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share